<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00747409</url>
  </required_header>
  <id_info>
    <org_study_id>AnaHum</org_study_id>
    <nct_id>NCT00747409</nct_id>
  </id_info>
  <brief_title>Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes</brief_title>
  <official_title>Randomized, Long-Term Study About the Effects of Analogue Versus Human Insulin Based Regimens (Insulin Detemir and Aspart Versus NPH- and Regular Human Insulin) on Metabolic Control and Myocardial Function in People With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Munich Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Munich Municipal Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compared to human insulins analogue insulins offer the option of optimizing metabolism also
      in type 2 diabetes. Especially, fast acting insulin analogues lower postprandial glucose
      levels more effectively than human regular insulin. However, it is not known whether therapy
      with analogue insulins can also improve the subclinically impaired myocardial function in
      type 2 diabetes. This prospective, randomized, open long term study compared the effects of a
      basal-bolus insulin therapy with analogue insulins versus human insulins on metabolic control
      and systolic and diastolic myocardial function, testing the hypothesis that optimized
      postprandial glucose control improves cardiac function and cardiovascular risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single centre, long term (24-48 months), therapy controlled and randomised study
      with blinded analysis of the ultrasound data in 120 patients with type 2 diabetes mellitus
      and with previous insulin therapy. After recruitment and informed consent, patients are
      randomized to two treatment arms according to a randomisation protocol which takes into
      account age and absence or presence of cardiovascular events in each patient's history.

      In one treatment arm, the intensive insulin therapy is based on human insulin (insulin NPH
      and regular human insulin) while in the other arm, the intensive insulin therapy is based on
      analogue insulin (insulin detemir and insulin aspart). Both treatment arms will be titrated
      to identical glycemic goals (fasting blood glucose &lt;110 mg/dL and post prandial blood glucose
      &lt;150 mg/dL).

      All patients will be updated in their skills of self medication by the departmental diabetic
      teaching programme und will receive life style instructions during each visit. Furthermore,
      they are encouraged to keep records of any episode of hypoglycemia throughout the study.
      Outpatient visits for metabolic control are every 3 months and ultrasound and blood tests
      every 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2004</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postprandial blood glucose at the end of the study and its change from baseline.</measure>
    <time_frame>24-48 months treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>diastolic myocardial function</measure>
    <time_frame>24-48 months treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Hum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use of human regular insulin and NPH insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ana</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use of insulin aspart and insulin detemir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart and detemir (NovoRapid, Levemir)</intervention_name>
    <description>use of basal-bolus therapy with insulin aspart and detemir</description>
    <arm_group_label>Ana</arm_group_label>
    <other_name>Insulin NovoRapid, Insulin Levemir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human regular insulin and NPH insulin (Actrapid, Protaphne)</intervention_name>
    <description>basal-bolus therapy with human regular and NPH insulin</description>
    <arm_group_label>Hum</arm_group_label>
    <other_name>Insulin Actrapid, Insulin Protaphne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes, insulin therapy

        Exclusion Criteria:

          -  type 1 diabetes, BMI &gt;40, pregnancy,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra-Maria Schumm-Draeger, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Munich Academic Teaching Hospital Bogenhausen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helene von Bibra, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Munich Academic Teaching Hospital Bogenhausen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Staedt. Klinikum Muenchen Bogenhausen</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Bretzel RG, Arnolds S, Medding J, Linn T. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care. 2004 May;27(5):1023-7.</citation>
    <PMID>15111514</PMID>
  </reference>
  <reference>
    <citation>von Bibra H, Hansen A, Dounis V, Bystedt T, Malmberg K, Ryd√©n L. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart. 2004 Dec;90(12):1483-4.</citation>
    <PMID>15547039</PMID>
  </reference>
  <reference>
    <citation>Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia. 1999 Sep;42(9):1050-4. Erratum in: Diabetologia 1999 Dec;42(12):1444.</citation>
    <PMID>10447514</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2008</study_first_posted>
  <last_update_submitted>September 4, 2008</last_update_submitted>
  <last_update_submitted_qc>September 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Petra-Maria Schumm-Draeger</name_title>
    <organization>Munich Municipal Hospital</organization>
  </responsible_party>
  <keyword>postprandial glucose, diastolic function, analogue insulins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

